References
- Anagnostou, E., Aman, M. G., Handen, B. L., Sanders, K. B., Shui, A., Hollway, J. A., Brian, J., Arnold, L. E., Capano, L., Hellings, J. A., Butter, E., Mankad, D., Tumuluru, R., Kettel, J., Newsom, C. R., Hadjiyannakis, S., Peleg, N., Odrobina, D., McAuliffe-Bellin, S., Zakroysky, P., … Veenstra-VanderWeele, J. (2016). Metformin for Treatment of Overweight Induced by Atypical Antipsychotic Medication in Young People With Autism Spectrum Disorder: A Randomized Clinical Trial. JAMA psychiatry, 73(9), 928–937. https://doi.org/10.1001/jamapsychiatry.2016.1232
- Freyberg, Z., Aslanoglou, D., Shah, R., Ballon, J.S., 2017. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Frontiers in Neuroscience.https://doi.org/10.3389/fnins.2017.00432
- Institute for Health Metrics and Evaluation (IHME) (2018). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME, 25 p.
- International Diabetes Federation (IDF) (2015). Diabetes Atlas. 7th ed. Vancouver, Canada. Available at: https://www.idf.org/e-library/epidemiology-research/diabetes-atlas
- Jungsun, L. (2019). Metabolic Side Effects of Antipsychotic Medication: An Overview. J Korean Neuropsychiatr Assoc, 58(1):18-28. doi:10.4306/jknpa.2019.58.1.18
- Maruta, N. O., Yaroslavtsev, S. O. (2015). Schizophrenia with comorbid mental and behavioral disorders (The structure of comorbid pathology, diagnostic criteria, prognostic factors and regularities of formation ). Medical psychology, 4: 46-50.
- Order of the Ministry of Health of Ukraine dated 21.12.2012 No.1118 “On Approving and Implementation of Medical and Technical Documents on the Standardization of Medical Care in Type 2 Diabetes”. (In Ukrainian). Available at: https://zakon.rada.gov.ua/rada/show/v1118282-12#Text
- Romash, I.R. (2016, a). Endogenous insulin and glucose concentration in patients with paranoid schizophrenia treated with atypical antipsychotics. The Pharma Innovation Journal, 5(4): 43-45. http://www.thepharmajournal.com/archives/2016/vol5issue4/PartA/5-3-17.pdf
- Romash, I.R. (2016,b) Comparative analysis of neurological symptoms with stagnation of risperidone and haloperidol in patients with schizophrenia. Likarsʹka sprava, 3-4:81-86.
- Siskind, D. J., Leung, J., Russell, A. W., Wysoczanski, D., & Kisely, S. (2016). Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PloS one, 11(6), e0156208. https://doi.org/10.1371/journal.pone.0156208
- Siskind, D., Friend, N., Russell, A., McGrath, J. J., Lim, C., Patterson, S., Flaws, D., Stedman, T., Moudgil, V., Sardinha, S., Suetani, S., Kisely, S., Winckel, K., & Baker, A. (2018). CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine. BMJ open, 8(3), e021000. https://doi.org/10.1136/bmjopen-2017-021000
- Oh, G.H., Yu, J.C., Choi, K.S. (2015)Simultaneous Comparison of Efficacy and Tolerability of Second-Generation Antipsichotics in Schizophrenia: Mixed-Treatment Comparison Analisis Based on Head-to Head Trial Data. Psychiatry Investig,12 (1):46-54